Showing results (621-630 of 689) with videos related to
Sort By:
Pageof 69
Circulation|January 30, 2026
Systemic Embolic Events in Atrial Fibrillation: An Individual Patient Data Meta-analysis of 71 683 Participants Randomized to NOAC Versus WarfarinSamer Al Said, Eugene Braunwald, Michael G Palazzolo, et al.American Heart Journal|October 3, 2002
Low-molecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention: an expert consensusDean J Kereiakes, Gilles Montalescot, Elliott M Antman, et al.Circulation|February 11, 2004
Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction 18) substudyStephen D Wiviott, Christopher P Cannon, David A Morrow, et al.Thrombosis and Haemostasis|March 9, 2012
Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillationDaniel E Salazar, Jeanne Mendell, Helen Kastrissios, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 8, 2006
Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conferenceR Hassan, R Alexander, K Antman, et al.Bone Marrow Transplantation|November 18, 1998
High-dose thiotepa and etoposide-based regimens with autologous hematopoietic support for high-risk or recurrent CNS tumors in children and adultsK P Papadopoulos, J H Garvin, M Fetell, et al.Circulation|June 14, 2000
High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: results from TIMI (thrombolysis in myocardial infarction) 14S A Coulter, C P Cannon, K A Ault, et al.Journal of General Internal Medicine|January 16, 2008
Prediction of one-year survival in high-risk patients with acute coronary syndromes: results from the SYNERGY trialKenneth W Mahaffey, Qinghong Yang, Karen S Pieper, et al.JAMA|November 24, 2005
High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trialKenneth W Mahaffey, Marc Cohen, Jyotsna Garg, et al.JACC. Advances|July 23, 2026
Heterogeneity of Treatment Effect of DOACs vs Warfarin in Atrial FibrillationSamer Al Said, Andrea Bellavia, Eugene Braunwald, et al.Pageof 69